Sitagliptin and heart failure hospitalization in patients with type 2 diabetes
Journal
Oncotarget
Journal Volume
7
Journal Issue
38
Pages
62687-62696
Date Issued
2016
Author(s)
Abstract
This study evaluated the risk of heart failure hospitalization in a 1:1 matched pair sample of sitagliptin ever and never users derived from the Taiwan's National Health Insurance. A total of 85,859 ever users and 85,859 never users matched on 8 digits of propensity score were followed for the first event of heart failure hospitalization until December 31, 2011. The treatment effect (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. Additionally, adjusted hazard ratios for heart failure were estimated for the baseline characteristics in sitagliptin ever users. Results showed that the incidence of heart failure hospitalization was 1,020.16 and 832.54 per 100,000 personyears, respectively, for ever and never users, with an overall hazard ratio (95% confidence intervals) of 1.262 (1.167-1.364). While compared to never users, the respective hazard ratio for the first, second, and third tertile of cumulative duration < 3.7, 3.7-10.3 and > 10.3 months was 2.721 (2.449-3.023), 1.472 (1.318-1.645) and 0.515 (0.447-0.594). Older age, longer diabetes duration, male sex, and use of insulin, sulfonylurea, calcium channel blockers, aspirin, ticlopidine, clopidogrel and dipyridamole were significantly associated with a higher risk in sitagliptin users, but dyslipidemia and use of metformin and statin were protective. In conclusion, sitagliptin increases the risk of heart failure hospitalization within one year of its use, but reduces the risk thereafter. Some factors predisposing to sitagliptin-related heart failure are worthy of attention in clinical practice.
Subjects
Heart failure; Hospitalization; Incretin; Sitagliptin; Taiwan
SDGs
Other Subjects
acetylsalicylic acid; calcium channel blocking agent; clopidogrel; dipyridamole; insulin; metformin; sitagliptin; sulfonylurea; ticlopidine; antidiabetic agent; sitagliptin; adult; age; Article; cardiovascular risk; cohort analysis; comparative study; controlled study; disease association; disease duration; drug effect; drug exposure; drug use; dyslipidemia; female; heart failure; hospitalization; human; incidence; major clinical study; male; middle aged; non insulin dependent diabetes mellitus; risk factor; sex difference; Taiwan; treatment duration; aged; complication; diabetic complication; health insurance; heart failure; hospitalization; non insulin dependent diabetes mellitus; probability; proportional hazards model; regression analysis; Adult; Aged; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Insurance, Health; Male; Middle Aged; Probability; Proportional Hazards Models; Regression Analysis; Sitagliptin Phosphate; Taiwan
Publisher
Impact Journals LLC
Type
journal article